Ligand Pharmaceuticals Incorporated LGND

301.52 2.48 0.83% as of 25 Sep
Market cap
$6.1B
P/E
30.1×

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
268.09 167.13 131.31 196.25 241.54 163.56 120.28 251.45 141.10 108.97
Revenue Growth
60.40% 27.28% (33.09%) (18.75%) 47.68% 35.98% (52.17%) 78.21% 29.48% 51.53%
Cost of Revenue
14.55 11.07 10.51 52.83 62.18 30.42 11.35 6.34 5.37 5.57
Gross Profit
253.54 156.06 120.80 143.42 179.37 133.14 108.94 245.12 135.74 103.40
R&D Expenses
81.18 21.43 24.54 36.08 32.11 40.50 55.91 27.86 26.89 21.22
SG&A Expenses
92.45 78.65 52.79 70.06 46.79 60.01 41.88 37.73 28.65 27.65
Operating Income
41.00 (22.61) 11.94 3.04 103.85 37.50 807.08 163.73 68.08 43.89
Non-operating Income/Expense
117.96 25.12 51.72 32.97 (31.65) (36.21) (10.44) 9.60 (10.84) (35.92)
Non-operating Interest Expenses
4.72 3.04 0.66 1.80 19.62 27.42 35.75 48.28 13.46 12.84
EBT
158.96 2.52 63.66 36.01 72.21 1.29 796.64 173.33 57.23 7.96
Income Tax Provision
34.51 6.55 9.84 41.23 (4.15) (5.31) 167.34 30.01 44.68 10.33
Income after Tax
124.45 (4.03) 53.82 (5.22) 76.35 6.60 629.30 143.32 12.56 (2.37)
Dividends (Preferred)
— — — — — — — — — 0.00
Net Income Common
124.45 (4.03) 52.15 (33.36) 57.14 (2.98) 629.30 143.32 12.56 (1.64)
EPS (Basic)
6.44 (0.22) 3.02 (1.98) 3.46 (0.18) 33.13 6.77 0.60 (0.08)
EPS (Diluted)
6.13 (0.22) 2.94 (1.98) 3.34 (0.18) 31.85 5.96 0.53 (0.08)
Shares (Basic, Weighted)
19.34 18.29 17.30 16.87 16.63 16.19 19.00 21.16 21.03 20.83
Shares (Diluted, Weighted)
20.29 18.29 17.76 16.87 17.25 16.83 19.76 24.07 23.48 20.83
Gross Margin
94.57% 93.37% 91.99% 73.08% 74.26% 81.40% 90.57% 97.48% 96.20% 94.89%
EBIT Margin
15.29% (13.53%) 9.09% 1.55% 42.99% 22.93% 670.99% 65.11% 48.25% 40.27%
EBT margin
59.29% 1.51% 48.48% 18.35% 29.89% 0.79% 662.31% 68.93% 40.56% 7.30%
Net Profit Margin
46.42% (2.41%) 39.72% (17.00%) 23.66% (1.82%) 523.19% 57.00% 8.90% (1.50%)
Free Cash Flow Margin
18.02% 50.76% (2.93%) 61.16% 29.20% 31.48% (26.51%) 72.85% 66.24% 37.80%
EBITDA
71.09 11.79 47.39 55.32 171.60 90.02 870.52 216.95 91.33 66.45
EBIT
41.00 (22.61) 11.94 3.04 103.85 37.50 807.08 163.73 68.08 43.89
Income from Continuous Operations
124.45 (4.03) 53.82 (5.22) 76.35 6.60 629.30 143.32 12.56 (2.37)
Income from Discontinued Operations
— — (1.66) (28.14) (19.21) (9.58) — 0.00 0.00 0.73
Consolidated Net Income/Loss
124.45 (4.03) 52.15 (33.36) 57.14 (2.98) 629.30 143.32 12.56 (1.64)
EPS (Basic, from Continuous Ops)
6.44 (0.22) 3.11 (0.31) 4.59 0.41 33.13 6.77 0.60 (0.11)
EPS (Basic, from Discontinued Ops)
— — (0.10) (1.67) (1.16) (0.59) — — — 0.04
EPS (Basic, Consolidated)
6.44 (0.22) 3.02 (1.98) 3.44 (0.18) 33.13 6.77 0.60 (0.08)
EPS (Diluted, from Cont. Ops)
6.13 (0.22) 3.03 (0.31) 4.43 0.39 31.85 5.96 0.53 (0.11)
EPS (Diluted, from Disc. Ops)
— — 0.00 0.00 0.00 0.00 — — — 0.00
Shares (Diluted, Average)
20.29 18.29 17.76 16.87 17.25 16.19 19.76 24.07 23.48 20.83
EPS (Diluted, Consolidated)
6.13 (0.22) 2.94 (1.98) 3.31 (0.18) 31.85 5.96 0.53 (0.08)
EBITDA Margin
26.52% 7.05% 36.09% 28.19% 71.04% 55.04% 723.73% 86.28% 64.72% 60.98%
Operating Cash Flow Margin
18.41% 58.07% 37.75% 70.24% 32.62% 33.37% (24.39%) 77.18% 62.77% 55.73%

Fold the line items

In millions of $ except per-share values · columns are period end dates